Drug Profile
Research programme: urokinase inhibitors - Heidelberg Pharma/4SC
Alternative Names: Urokinase inhibitors research programme - Heidelberg Pharma/4SCLatest Information Update: 20 Nov 2017
Price :
$50
*
At a glance
- Originator 4SC; Wilex
- Class
- Mechanism of Action Urokinase-type plasminogen activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 28 Jun 2002 Discontinued - Preclinical for Cancer in Germany (unspecified route)
- 14 Jan 2002 Preclinical development for Cancer in Germany (unspecified route)